Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults

OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompr...

Descripción completa

Detalles Bibliográficos
Autores principales: Atwood, Mark, Beausoleil, Linda, Breton, Marie-Claude, Laferriere, Craig, Sato, Reiko, Weycker, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Quantitative Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/
https://www.ncbi.nlm.nih.gov/pubmed/29981104
http://dx.doi.org/10.17269/s41997-018-0050-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/
https://www.ncbi.nlm.nih.gov/pubmed/29981104
http://dx.doi.org/10.17269/s41997-018-0050-9

Ejemplares similares